

## POST MENOPAUSAL HYPERTENSION – PATHOPHYSIOLOGY, MOLECULAR MECHANISM, THERAPEUTIC STRATEGIES AND NEWER APPROACHES

Dr. Virendra Kushwaha\*, Dr. Pooja Agrawal, Dr. B. K. Shoraisham, Dr. Mohd. Aamir, Dr. Shivangi Raj Singh, Dr. Mayuri Krishnan

India.



\*Corresponding Author: Dr. Virendra Kushwaha

India.

DOI: <https://doi.org/10.5281/zenodo.20444074>

**How to cite this Article:** Dr. Virendra Kushwaha\*, Dr. Pooja Agrawal, Dr. B. K. Shoraisham, Dr. Mohd. Aamir, Dr. Shivangi Raj Singh, Dr. Mayuri Krishnan (2026). Post Menopausal Hypertension - Pathophysiology, Molecular Mechanism, Therapeutic Strategies and Newer Approaches. European Journal of Pharmaceutical and Medical Research, 13(6), 103–115. This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 06/05/2026

Article Revised on 26/05/2026

Article Published on 01/06/2026

### ABSTRACT

Menopause is a complex biological transition characterized by permanent cessation of ovarian function and progressive estrogen deficiency, resulting in profound cardiovascular, metabolic, neuroendocrine, and vascular alterations. Among these consequences, postmenopausal hypertension has emerged as a major cardiovascular disorder and an important contributor to morbidity and mortality in aging women. The pathophysiology is multifactorial and involves endothelial dysfunction, arterial stiffness, oxidative stress, chronic low-grade inflammation, activation of the renin–angiotensin–aldosterone system, sympathetic nervous system overactivity, mitochondrial dysfunction, metabolic syndrome, and vascular remodeling. These interconnected mechanisms accelerate vascular aging and increase susceptibility to coronary artery disease, stroke, heart failure with preserved ejection fraction, chronic kidney disease, and cognitive decline. Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause; however, its cardiovascular effects are influenced by age at initiation, timing relative to menopause onset, route of administration, hormonal formulation, and baseline cardiovascular risk profile. Contemporary evidence supports individualized and risk-stratified use of MHT, particularly in symptomatic women younger than 60 years or within 10 years of menopause onset. Recent advances in menopause neurobiology have identified hypothalamic neurokinin pathways as central mediators of vasomotor symptoms, leading to the development of novel non-hormonal therapies such as neurokinin receptor antagonists. In addition, phytoestrogens, microbiome-based approaches, pharmacogenomics, artificial intelligence-assisted risk prediction, and precision medicine strategies are emerging as promising future directions in menopause management.

**KEYWORDS:** Menopause, Postmenopausal hypertension, Menopausal hormone therapy, Endothelial dysfunction, Estrogen deficiency, Neurokinin receptor antagonists.

### INTRODUCTION

Menopause represents a universal physiological transition characterized by permanent cessation of menstruation secondary to ovarian follicular depletion and progressive decline in ovarian steroidogenesis. Clinically, natural menopause is diagnosed retrospectively after 12 consecutive months of amenorrhea in the absence of pathological, pharmacological, or physiological causes. The average age of menopause is approximately 50–51 years globally, although substantial ethnic, genetic, nutritional, environmental, and socioeconomic variability exists.<sup>[1]</sup>

With increasing life expectancy, women now spend nearly one-third of their lifespan in the postmenopausal state, resulting in growing attention toward menopause-associated cardiovascular and metabolic disorders.<sup>[2]</sup>

Cardiovascular disease remains the leading cause of mortality among women worldwide. During reproductive life, women generally exhibit lower blood pressure, improved endothelial function, reduced arterial stiffness, and lower cardiovascular risk compared with age-matched men. This relative cardioprotection is largely attributed to the vasodilatory, antioxidant, anti-inflammatory, and metabolic effects of endogenous

estrogens. Estrogen promotes nitric oxide-mediated vasodilation, suppresses oxidative stress, modulates lipid metabolism, attenuates inflammatory signaling, and improves vascular endothelial function.<sup>[3]</sup> However, this cardiovascular advantage progressively diminishes during the menopausal transition and declines significantly after menopause.

Postmenopausal hypertension is now recognized as a distinct cardiovascular phenotype characterized by isolated systolic hypertension, arterial stiffness, endothelial dysfunction, salt sensitivity, autonomic dysregulation, and enhanced susceptibility to hypertension-mediated target-organ damage. The pathophysiology is multifactorial and involves estrogen deficiency, vascular aging, oxidative stress, chronic inflammation, activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system overactivity, metabolic syndrome, and vascular remodeling.<sup>[4]</sup>

These mechanisms collectively accelerate atherosclerosis and cardiovascular aging.

The clinical implications are substantial. Postmenopausal hypertension is associated with coronary artery disease, stroke, heart failure with preserved ejection fraction (HFpEF), chronic kidney disease, peripheral arterial disease, cognitive decline, and vascular dementia. Women frequently demonstrate unique cardiovascular phenotypes including coronary microvascular dysfunction and HFpEF, conditions strongly linked with arterial stiffness and endothelial dysfunction.

Menopausal hormone therapy (MHT), previously termed hormone replacement therapy, remains the most effective treatment for vasomotor symptoms and prevention of menopause-related bone loss. However, publication of the Women's Health Initiative (WHI) trial significantly altered global prescribing practices because of concerns regarding venous thromboembolism, stroke, coronary artery disease, and breast cancer.<sup>[5]</sup> Subsequent reanalyses introduced the “timing hypothesis,” suggesting that cardiovascular outcomes depend strongly on age at initiation, time since menopause, and baseline vascular health.

Recent advances in menopause neurobiology have identified the role of hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons in vasomotor symptom generation. This discovery has led to development of neurokinin receptor antagonists such as fezolinetant and elinzanetant as effective non-hormonal therapeutic options.<sup>[6]</sup> Simultaneously, increasing attention has focused on phytoestrogens and precision medicine approaches aimed at individualized menopause management.

This review discusses the epidemiology, molecular pathophysiology, cardiovascular implications,

pharmacological management, and future precision medicine approaches in postmenopausal hypertension and menopause therapeutics.

### **Epidemiology and Clinical Burden of Postmenopausal Hypertension**

Hypertension is among the most important modifiable cardiovascular risk factors worldwide and contributes substantially to global morbidity and mortality. In women, the epidemiology of hypertension follows a distinct life-course pattern. During early adulthood, men generally demonstrate higher blood pressure levels than women. However, this sex difference progressively narrows during the menopausal transition and reverses after menopause, when women exhibit a steeper rise in systolic blood pressure and eventually surpass men in hypertension prevalence.<sup>[7-10]</sup>

Large epidemiological studies indicate that approximately 41% of postmenopausal women develop hypertension, while more than 75% of women older than 60 years are hypertensive in several populations.<sup>[8-10]</sup> This burden is expected to rise further because more than one billion women globally are projected to be postmenopausal by 2030.<sup>[11]</sup>

The menopausal transition itself appears to independently influence blood pressure regulation beyond chronological aging alone. Women in late menopausal transition stages often exhibit significantly higher systolic and diastolic blood pressure compared with women in early transition phases. Premature menopause and surgical menopause are associated with even greater cardiovascular risk because abrupt estrogen deprivation accelerates endothelial dysfunction, arterial stiffness, and metabolic abnormalities.<sup>[12]</sup>

Postmenopausal hypertension differs from hypertension observed in younger women. It is frequently characterized by

- Increased arterial stiffness
- Isolated systolic hypertension
- Widened pulse pressure
- Salt sensitivity
- Endothelial dysfunction
- Greater blood pressure variability
- Enhanced vascular remodeling

These alterations contribute to increased risk of coronary artery disease, stroke, chronic kidney disease, HFpEF, peripheral arterial disease, and cognitive impairment.<sup>[13-15]</sup>

Metabolic syndrome further intensifies cardiovascular burden in postmenopausal women. Estrogen deficiency promotes central adiposity, insulin resistance, dyslipidemia, chronic inflammation, and oxidative stress. Consequently, cardiometabolic risk rises substantially after menopause, particularly in South Asian populations where visceral adiposity and diabetes frequently occur at lower body mass index thresholds.<sup>[16]</sup>

Vasomotor symptoms also possess important cardiovascular implications. Hot flushes and night sweats affect nearly 80% of menopausal women and are increasingly associated with endothelial dysfunction, carotid intima-media thickening, coronary artery calcification, arterial stiffness, and inflammatory activation.<sup>[17]</sup> Severe vasomotor symptoms may therefore serve as early markers of vascular dysfunction.

### **Molecular Pathophysiology of Postmenopausal Hypertension**

#### **Neuroendocrine Basis of Cardiovascular Dysfunction**

Menopause is fundamentally a neuroendocrine process involving dysregulation of the hypothalamic–pituitary–ovarian axis. Estrogen exerts extensive cardiovascular effects through estrogen receptor alpha (ER $\alpha$ ), estrogen receptor beta (ER $\beta$ ), and G protein-coupled estrogen receptor (GPER), which are distributed throughout vascular endothelium, vascular smooth muscle, myocardium, kidneys, adipose tissue, and autonomic centers of the central nervous system.

Estrogen signaling occurs via genomic and non-genomic pathways. Genomic pathways regulate transcription of genes involved in nitric oxide synthesis, antioxidant defense, mitochondrial function, and inflammatory signaling. Non-genomic pathways activate PI3K/Akt signaling, MAP kinase pathways, calcium signaling, and endothelial nitric oxide synthase (eNOS) activation, thereby producing rapid vasodilatory effects.<sup>[18-19]</sup>

Following menopause, estrogen deficiency disrupts these protective mechanisms and promotes endothelial dysfunction, vascular inflammation, neurohormonal activation, and arterial remodeling.

#### **Endothelial Dysfunction**

Endothelial dysfunction represents one of the earliest molecular abnormalities in postmenopausal hypertension. Under physiological conditions, estrogen stimulates endothelial nitric oxide synthase and enhances nitric oxide bioavailability. Nitric oxide promotes vasodilation, inhibits platelet aggregation, suppresses leukocyte adhesion, and attenuates vascular smooth muscle proliferation.<sup>[20]</sup>

After menopause, reduced estrogen levels lead to diminished nitric oxide synthesis and increased endothelin-1 activity. Oxidative stress further inactivates nitric oxide through peroxynitrite formation, thereby establishing a cycle of endothelial injury and impaired vasodilation.

#### **Endothelin-Mediated Vascular Dysfunction**

Endothelin-1 is among the most potent endogenous vasoconstrictors. Estrogen deficiency enhances endothelin synthesis and vascular sensitivity to endothelin signaling. Activation of endothelin receptors promotes

- Vasoconstriction

- Smooth muscle proliferation
- Fibrosis
- Oxidative stress
- Vascular remodeling

Endothelin additionally interacts synergistically with RAAS and sympathetic pathways, thereby amplifying hypertension progression.<sup>[21,22]</sup>

#### **Renin–Angiotensin–Aldosterone System Activation**

The renin–angiotensin–aldosterone system plays a central role in postmenopausal vascular dysfunction. Estrogen normally suppresses several RAAS components; consequently, menopause results in increased plasma renin activity, elevated angiotensin II levels, and enhanced aldosterone secretion.<sup>[23]</sup>

Angiotensin II promotes

- Vasoconstriction
- Sodium retention
- Oxidative stress
- Inflammation
- Vascular smooth muscle hypertrophy
- Fibrosis

Aldosterone contributes further to endothelial dysfunction, arterial stiffness, myocardial fibrosis, and sympathetic activation.<sup>[24,25]</sup>

#### **Oxidative Stress and Mitochondrial Dysfunction**

Oxidative stress is a major contributor to vascular aging after menopause. Estrogen possesses intrinsic antioxidant effects and regulates endogenous antioxidant enzymes. Estrogen deficiency therefore leads to increased reactive oxygen species generation and impaired antioxidant defenses.<sup>[27]</sup>

Major vascular consequences include

- Lipid oxidation
- Endothelial injury
- Vascular inflammation
- Collagen deposition
- Elastin fragmentation
- Arterial calcification

Mitochondrial dysfunction additionally promotes endothelial senescence and impaired vascular repair.<sup>[28]</sup>

#### **Sympathetic Nervous System Overactivity**

Estrogen modulates autonomic balance by suppressing sympathetic outflow and enhancing parasympathetic activity. Menopause therefore results in increased sympathetic tone, elevated norepinephrine release, impaired baroreceptor sensitivity, and enhanced vasoconstriction.<sup>[29]</sup>

Persistent sympathetic overactivity contributes to

- Increased systemic vascular resistance
- Elevated heart rate
- RAAS activation
- Arterial stiffness
- Left ventricular hypertrophy

Vasomotor symptoms and sleep disturbance may further intensify autonomic dysregulation.<sup>[30]</sup>

### **Obesity, Insulin Resistance, and Metabolic Dysfunction**

Menopause promotes redistribution of adipose tissue toward a visceral pattern strongly associated with insulin resistance and inflammation. Visceral adipose tissue acts as an endocrine organ producing leptin, resistin, TNF- $\alpha$ , IL-6, and angiotensinogen.<sup>[31,32]</sup>

These adipokines promote

- Endothelial dysfunction
- Sympathetic activation
- Oxidative stress
- RAAS activation
- Sodium retention
- Chronic inflammation

Obstructive sleep apnea, increasingly prevalent in obese postmenopausal women, further worsens sympathetic activation and endothelial injury.<sup>[33]</sup>

### **Arterial Stiffness and Vascular Remodeling**

Arterial stiffness is a hallmark of postmenopausal vascular aging. Structural vascular alterations include:

- Elastin fragmentation
- Collagen accumulation
- Extracellular matrix remodeling
- Vascular calcification

These changes increase pulse wave velocity and systolic blood pressure, producing isolated systolic hypertension.<sup>[34,35]</sup>

Important markers of arterial stiffness include

- Pulse wave velocity
- Augmentation index
- Central systolic blood pressure
- Pulse pressure

Arterial stiffness contributes significantly to HFpEF, stroke, chronic kidney disease, and cognitive decline.<sup>[36]</sup>

### **Inflammatory Mechanisms in Postmenopausal Hypertension**

Menopause is increasingly recognized as a chronic low-grade inflammatory state. Estrogen normally suppresses inflammatory signaling pathways and cytokine production. Following menopause, inflammatory mediators including TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and C-reactive protein become elevated.<sup>[39,40]</sup>

These inflammatory pathways contribute to

- Endothelial injury
- Vascular fibrosis
- Oxidative stress
- Arterial stiffness
- Atherosclerosis

Activated macrophages infiltrate vascular tissues and release cytokines, matrix metalloproteinases, and reactive oxygen species, thereby accelerating vascular remodeling and plaque formation.<sup>[41,42]</sup>

Inflammation is also closely linked with insulin resistance and metabolic syndrome, creating a self-perpetuating cycle of cardiometabolic dysfunction.<sup>[44]</sup>

### **Neurokinin Pathways and Vasomotor Symptoms**

A major advance in menopause neurobiology has been the discovery of hypothalamic KNDy neurons co-expressing kisspeptin, neurokinin B, and dynorphin. These neurons regulate thermoregulation and gonadotropin-releasing hormone secretion.

Estrogen withdrawal increases neurokinin B signaling, destabilizes hypothalamic thermoregulation, narrows the thermoneutral zone, and triggers hot flashes and night sweats.<sup>[51-53]</sup>

This mechanistic understanding has led to development of neurokinin receptor antagonists as targeted non-hormonal therapies.

### **Cardiovascular Consequences of Postmenopausal Hypertension**

#### **Coronary Artery Disease**

Endothelial dysfunction, inflammation, oxidative stress, and arterial remodeling accelerate coronary atherosclerosis in postmenopausal women. Women frequently demonstrate coronary microvascular dysfunction and diffuse atherosclerotic disease.<sup>[57,58]</sup>

#### **Stroke**

Hypertension substantially increases ischemic and hemorrhagic stroke risk after menopause. Chronic endothelial dysfunction and arterial stiffness impair cerebral autoregulation and microvascular integrity.<sup>[59]</sup>

#### **Heart Failure with Preserved Ejection Fraction**

HFpEF is particularly common among hypertensive postmenopausal women. The pathophysiology involves:

- Diastolic dysfunction
- Myocardial fibrosis
- Endothelial dysfunction
- Vascular stiffness
- Microvascular inflammation

Chronic hypertension increases left ventricular afterload and promotes concentric hypertrophy.<sup>[60]</sup>

#### **Chronic Kidney Disease**

Hypertension progressively damages renal microvasculature and contributes to nephrosclerosis, sodium retention, and worsening RAAS activation.<sup>[58]</sup>

#### **Cognitive Decline and Dementia**

Vascular dysfunction, oxidative stress, inflammation, and cerebral hypoperfusion contribute significantly to cognitive impairment and vascular dementia in postmenopausal women.<sup>[61]</sup>

### Pharmacotherapy of Menopausal Hormone Therapy Historical Evolution of MHT

Estrogen therapy was historically prescribed not only for symptom control but also for prevention of osteoporosis and cardiovascular disease. However, publication of the WHI trial dramatically altered perceptions regarding MHT safety because of increased risks of venous thromboembolism, stroke, and breast cancer.<sup>[5]</sup>

Subsequent analyses revealed that many WHI participants were older women with established vascular disease and delayed initiation of therapy. These findings led to development of the “timing hypothesis,” suggesting that cardiovascular outcomes depend on timing of MHT initiation relative to menopause onset.<sup>[20]</sup>

### Principles of Modern MHT

Current guidelines recommend MHT primarily for

- Moderate-to-severe vasomotor symptoms
- Genitourinary syndrome of menopause
- Prevention of early postmenopausal bone loss

MHT is generally most appropriate in symptomatic women younger than 60 years or within 10 years of menopause onset.<sup>[66,67]</sup>

Important considerations include

- Age
- Cardiovascular risk
- Breast cancer risk
- Venous thromboembolism risk
- Presence of uterus
- Metabolic profile
- Patient preference

### Estrogen Therapy

Estrogen-only therapy is reserved mainly for women following hysterectomy because unopposed estrogen increases endometrial cancer risk.<sup>[69]</sup>

Common preparations include

- Oral estradiol
- Conjugated equine estrogen
- Transdermal estradiol patches
- Estradiol gels
- Vaginal estrogen preparations

### Combined Estrogen–Progestogen Therapy

Women with an intact uterus require progestogen addition to prevent endometrial hyperplasia. Combined regimens may be

- Continuous combined
- Sequential cyclic

Micronized progesterone and dydrogesterone appear metabolically favorable compared with older synthetic progestins.<sup>[73,74]</sup>

### Oral Versus Transdermal Estrogen

Oral estrogen undergoes first-pass hepatic metabolism and increases synthesis of clotting factors and

inflammatory proteins. Consequently, oral formulations are associated with higher thrombotic risk.<sup>[69]</sup>

Transdermal estradiol bypasses hepatic first-pass metabolism and exerts less effect on coagulation pathways, triglycerides, and inflammatory markers. It is increasingly preferred in women with obesity, hypertension, diabetes mellitus, migraine, or elevated VTE risk.

### Cardiovascular Effects of MHT

Potential beneficial vascular effects include

- Enhanced nitric oxide production
- Improved endothelial function
- Reduced vascular inflammation
- Improved lipid profile
- Better arterial compliance

However, thrombotic risk depends strongly on route of administration, age at initiation, and baseline cardiovascular status.<sup>[77,78]</sup>

### Breast Cancer Risk

Breast cancer risk varies according to:

- Duration of therapy
- Estrogen formulation
- Type of progestogen
- Dose
- Route of administration

Combined estrogen–progestogen therapy appears associated with greater breast cancer risk than estrogen-only therapy.<sup>[79]</sup>

### Contraindications to Systemic MHT

Systemic MHT is generally contraindicated in

- Breast cancer
- Estrogen-dependent malignancy
- Active liver disease
- Previous venous thromboembolism
- Active stroke or myocardial infarction
- Known thrombophilia

### Non-Hormonal Pharmacotherapy

#### SSRIs and SNRIs

Selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors are widely used for vasomotor symptoms. Agents include

- Paroxetine
- Venlafaxine
- Desvenlafaxine
- Escitalopram
- Citalopram

These drugs modulate hypothalamic serotonergic and noradrenergic pathways involved in thermoregulation.<sup>[80,81]</sup>

#### Gabapentin

Gabapentin is particularly effective for nocturnal hot flashes and sleep disturbance. Common adverse effects include dizziness, somnolence, and fatigue.

**Clonidine**

Clonidine modestly reduces vasomotor symptoms but is limited by adverse effects such as hypotension, dry mouth, and sedation.

**Oxybutynin**

Oxybutynin has demonstrated efficacy for vasomotor symptoms, particularly when urinary urgency coexists.<sup>[82]</sup>

**Neurokinin Receptor Antagonists****Fezolinetant**

Fezolinetant is a selective NK3 receptor antagonist approved for moderate-to-severe vasomotor symptoms. Clinical trials demonstrated significant reduction in hot flush frequency and severity with improvement in sleep quality and quality of life.<sup>[84,85]</sup>

**Elinzanetant**

Elinzanetant is a dual NK1/NK3 receptor antagonist currently under advanced investigation and represents an important future direction in mechanism-based menopause pharmacotherapy.<sup>[86]</sup>

**Phytoestrogens and Alternative Therapies**

Phytoestrogens are plant-derived compounds with estrogen-like biological activity. Major classes include

- Isoflavones
- Lignans
- Coumestans
- Stilbenes

Their actions depend on estrogen receptor affinity, dose, tissue distribution, microbiome composition, and endogenous estrogen levels.<sup>[87-89]</sup>

**Isoflavones**

Genistein and daidzein are the most extensively studied isoflavones.

Potential benefits include

- Improved endothelial function
- Reduction in oxidative stress
- Improved arterial compliance
- Modest lipid improvement
- Bone-protective effects

However, clinical responses vary substantially because only 30–50% of individuals are capable of converting daidzein into equol, a more potent metabolite.<sup>[96,97]</sup>

**Lignans**

Flaxseed-derived lignans possess antioxidant and mild lipid-lowering effects. Some studies suggest modest improvement in arterial stiffness and vasomotor symptoms.<sup>[98,99]</sup>

**Resveratrol**

Resveratrol exerts antioxidant, anti-inflammatory, endothelial, mitochondrial, and neuroprotective effects through activation of SIRT1 signaling pathways.<sup>[99]</sup>

Although phytoestrogens may provide mild-to-moderate symptom improvement, they are generally less effective than conventional MHT.<sup>[101]</sup>

**Precision Medicine and Future Directions**

Menopause management is increasingly shifting toward individualized precision medicine. Women differ substantially in

- Vasomotor symptom severity
- Cardiovascular risk
- Bone loss rate
- Breast cancer susceptibility
- Metabolic profile
- Therapeutic response

Precision medicine aims to tailor therapy according to genetics, biomarkers, microbiome composition, cardiovascular risk, and patient preference.<sup>[106]</sup>

**Cardiovascular and Thrombotic Risk Stratification**

Future menopause management may involve

- Coronary artery calcium scoring
- Endothelial biomarkers
- Pharmacogenomic testing
- Thrombophilia screening
- AI-guided cardiovascular prediction models

Women with elevated thrombotic risk may benefit from transdermal estrogen or non-hormonal therapies.

**Microbiome and Menopause**

The gut microbiome influences estrogen metabolism and phytoestrogen response. Future approaches may incorporate microbiome profiling and personalized probiotic interventions.<sup>[107]</sup>

**Artificial Intelligence**

AI-based systems may eventually integrate

- Hormonal biomarkers
- Genetic profile
- Cardiovascular imaging
- Lifestyle data
- Wearable-device information

These approaches may help predict MHT response and adverse-event risk.

**Emerging Therapeutic Agents**

Promising future therapies include

- Neurokinin receptor antagonists
- Estetrol
- Tissue-selective estrogen complexes
- Selective estrogen receptor modulators
- Gene-targeted therapies

Long-term safety and cardiovascular outcome data remain necessary.<sup>[108-110]</sup>

## Antihypertensive Therapy in Postmenopausal Women

### Principles of Antihypertensive Management in Postmenopausal Hypertension

Management of postmenopausal hypertension requires a comprehensive and individualized therapeutic approach because the pathophysiology differs substantially from hypertension observed in younger women and men. Postmenopausal women commonly exhibit isolated systolic hypertension, arterial stiffness, endothelial dysfunction, salt sensitivity, sympathetic nervous system overactivity, obesity-related metabolic dysfunction, and activation of the renin–angiotensin–aldosterone system (RAAS). Consequently, antihypertensive therapy should not only reduce blood pressure but also target the underlying vascular and metabolic abnormalities contributing to cardiovascular risk.<sup>[111]</sup>

Lifestyle modification remains the foundation of therapy and should accompany pharmacological treatment in all patients. Important interventions include:

- Dietary sodium restriction
- Weight reduction
- Regular aerobic exercise
- Resistance training
- Smoking cessation
- Moderation of alcohol intake
- Optimization of sleep quality
- Management of stress and depression

The Dietary Approaches to Stop Hypertension (DASH) diet has demonstrated beneficial effects on blood pressure, endothelial function, insulin resistance, and cardiovascular risk. Salt restriction is particularly important because many postmenopausal women exhibit salt-sensitive hypertension due to altered renal sodium handling and enhanced aldosterone activity.<sup>[112]</sup>

Current hypertension guidelines generally recommend treatment targets similar to those used in the general population; however, therapeutic selection in postmenopausal women should consider arterial stiffness, metabolic profile, cardiovascular disease, chronic kidney disease, osteoporosis risk, and menopausal symptoms.<sup>[113]</sup>

### Renin–Angiotensin–Aldosterone System Inhibitors Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE) inhibitors are among the most important antihypertensive agents in postmenopausal women because RAAS activation plays a central role in menopause-associated vascular dysfunction. ACE inhibitors reduce angiotensin II formation, improve endothelial function, decrease oxidative stress, and attenuate vascular remodeling.<sup>[114]</sup>

Potential benefits include

- Improved arterial compliance
- Reduction in vascular inflammation

- Decreased left ventricular hypertrophy
- Renal protection
- Reduction in proteinuria

ACE inhibitors may be particularly useful in postmenopausal women with:

- Diabetes mellitus
- Chronic kidney disease
- Heart failure
- Left ventricular dysfunction
- Metabolic syndrome

Commonly used ACE inhibitors include

- Ramipril
- Enalapril
- Perindopril
- Lisinopril

Adverse effects include cough, hyperkalemia, hypotension, renal dysfunction, and rarely angioedema.<sup>[115]</sup>

### Angiotensin Receptor Blockers

Angiotensin receptor blockers (ARBs) inhibit angiotensin II type 1 receptor signaling and provide many vascular benefits similar to ACE inhibitors while avoiding bradykinin-mediated cough.

ARBs improve endothelial function, reduce oxidative stress, decrease arterial stiffness, and attenuate vascular inflammation.<sup>116</sup> They are particularly valuable in women with obesity, insulin resistance, or metabolic syndrome because some ARBs demonstrate favorable metabolic effects.

Commonly used ARBs include

- Losartan
- Telmisartan
- Valsartan
- Olmesartan
- Candesartan

Telmisartan may provide additional metabolic benefits because of partial peroxisome proliferator-activated receptor-gamma (PPAR- $\gamma$ ) agonist activity.<sup>[117]</sup>

### Mineralocorticoid Receptor Antagonists

Aldosterone contributes significantly to arterial stiffness, endothelial dysfunction, myocardial fibrosis, and salt-sensitive hypertension in postmenopausal women. Consequently, mineralocorticoid receptor antagonists may provide important therapeutic benefit.

Spironolactone and eplerenone reduce sodium retention, improve vascular stiffness, and attenuate myocardial fibrosis. These drugs are especially useful in

- Resistant hypertension
- Primary aldosteronism
- Heart failure with preserved ejection fraction
- Obesity-associated hypertension

Spirolactone may additionally improve endothelial function and reduce vascular inflammation.<sup>[118]</sup> However, hyperkalemia and renal dysfunction require careful monitoring.

### Calcium Channel Blockers

Calcium channel blockers (CCBs) are highly effective in postmenopausal women because arterial stiffness and isolated systolic hypertension are prominent features of menopause-associated vascular aging.

Dihydropyridine calcium channel blockers produce potent vasodilation and effectively reduce systolic blood pressure.<sup>[119]</sup> Commonly used agents include

- Amlodipine
- Nifedipine
- Felodipine

Potential benefits include

- Reduction in arterial stiffness
- Improvement in coronary perfusion
- Reduction in stroke risk
- Effective control of isolated systolic hypertension

CCBs are especially useful in older postmenopausal women with widened pulse pressure and vascular stiffness.

Adverse effects include peripheral edema, headache, flushing, and gingival hyperplasia.

### Thiazide and Thiazide-Like Diuretics

Thiazide diuretics remain important first-line antihypertensive agents, particularly in salt-sensitive hypertension. Postmenopausal women often demonstrate enhanced sodium retention because of RAAS activation and altered renal sodium handling.

Common agents include

- Hydrochlorothiazide
- Chlorthalidone
- Indapamide

Chlorthalidone and indapamide may provide superior cardiovascular protection compared with hydrochlorothiazide because of longer duration of action and greater reduction in arterial stiffness.<sup>[120]</sup>

Thiazide therapy may additionally reduce urinary calcium excretion and contribute modestly to preservation of bone mineral density, which may be beneficial in postmenopausal women at risk of osteoporosis.

However, metabolic adverse effects such as

- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Hyperglycemia
- Dyslipidemia

must be considered carefully, especially in women with metabolic syndrome or diabetes mellitus.

### Beta-Adrenergic Blockers

Beta-blockers reduce sympathetic nervous system activity and may be useful in postmenopausal women with:

- Coronary artery disease
- Tachyarrhythmias
- Heart failure
- Anxiety-associated sympathetic activation
- Migraine

However, beta-blockers are generally less effective for isolated systolic hypertension and arterial stiffness compared with RAAS inhibitors and calcium channel blockers.<sup>[121]</sup>

Traditional beta-blockers such as atenolol may worsen insulin resistance and fatigue. In contrast, vasodilatory beta-blockers such as nebivolol and carvedilol possess more favorable metabolic and endothelial effects.

Nebivolol additionally enhances nitric oxide release and may improve endothelial function.<sup>[122]</sup>

### Combination Therapy

Many postmenopausal women require combination antihypertensive therapy because hypertension is often multifactorial and associated with arterial stiffness, obesity, and metabolic dysfunction.

Preferred combinations include

- ACE inhibitor or ARB + calcium channel blocker
- ACE inhibitor or ARB + thiazide diuretic
- Calcium channel blocker + thiazide diuretic

Combination therapy improves blood pressure control while targeting complementary pathophysiological mechanisms.

### Menopausal Hormone Therapy and Blood Pressure

The relationship between menopausal hormone therapy and blood pressure remains complex. Estrogen may improve endothelial function, nitric oxide bioavailability, arterial compliance, and vascular reactivity. However, blood pressure effects vary according to

- Route of administration
- Estrogen formulation
- Progestogen type
- Baseline cardiovascular status

Oral estrogen may increase hepatic angiotensinogen synthesis because of first-pass hepatic metabolism and may therefore increase blood pressure in some women.<sup>[123]</sup> In contrast, transdermal estradiol bypasses hepatic metabolism and generally exerts neutral or modestly favorable blood pressure effects.

Drospirenone-containing MHT formulations may provide additional blood pressure benefit because drospirenone possesses anti-mineralocorticoid activity.<sup>[124]</sup>

MHT should not be prescribed solely for treatment of hypertension; however, appropriately selected symptomatic women receiving MHT may experience modest improvement in vascular function.

### Resistant Hypertension in Postmenopausal Women

Resistant hypertension is increasingly common in postmenopausal women because of obesity, obstructive sleep apnea, arterial stiffness, chronic kidney disease, and aldosterone excess.

Important secondary contributors include

- Primary aldosteronism
- Obstructive sleep apnea
- Chronic kidney disease
- Medication non-adherence
- Excess dietary sodium
- Sympathetic overactivity

Evaluation should include assessment for secondary causes and target-organ damage.<sup>[125]</sup> Mineralocorticoid receptor antagonists are particularly effective in resistant hypertension associated with aldosterone-mediated vascular dysfunction.

### Cardiovascular Risk Reduction Beyond Blood Pressure Control

Management of postmenopausal hypertension should extend beyond blood pressure reduction alone and include comprehensive cardiovascular risk modification.

Important components include

- Lipid management
- Diabetes control
- Weight management
- Physical activity
- Smoking cessation
- Sleep optimization
- Treatment of depression and anxiety

Statins, antidiabetic therapy, exercise programs, and lifestyle interventions significantly reduce long-term cardiovascular risk and improve endothelial function.<sup>[126]</sup>

### Future Directions in Antihypertensive Therapy

Future therapeutic approaches may increasingly incorporate precision medicine strategies including

- Biomarker-guided therapy
- Pharmacogenomics
- AI-guided cardiovascular risk prediction
- Endothelial function assessment
- Microbiome-based interventions

Emerging therapies targeting inflammation, oxidative stress, endothelial dysfunction, and vascular aging may further improve cardiovascular outcomes in postmenopausal women.<sup>[127]</sup>

### CONCLUSION

Postmenopausal hypertension represents a unique and complex cardiovascular phenotype arising from the interaction of reproductive aging, neuroendocrine dysregulation, vascular remodeling, metabolic

dysfunction, inflammation, and autonomic imbalance. Estrogen deficiency plays a pivotal role in the development of endothelial dysfunction, oxidative stress, arterial stiffness, activation of the renin–angiotensin–aldosterone system, sympathetic overactivity, and chronic inflammatory signaling, all of which contribute to accelerated cardiovascular aging and increased risk of adverse cardiovascular outcomes. Consequently, postmenopausal women demonstrate increased susceptibility to coronary artery disease, stroke, heart failure with preserved ejection fraction, chronic kidney disease, and cognitive impairment.

Modern management of postmenopausal hypertension requires a comprehensive and individualized approach integrating lifestyle modification, cardiovascular risk reduction, antihypertensive therapy, and symptom-directed menopause management. Menopausal hormone therapy remains the gold standard for treatment of vasomotor symptoms and genitourinary syndrome of menopause, but its use should be guided by careful assessment of age, time since menopause, thrombotic risk, breast cancer risk, and overall cardiovascular profile. Transdermal estrogen formulations, metabolically favorable progestogens, and individualized treatment selection have improved the safety profile of contemporary MHT. Simultaneously, non-hormonal therapies including SSRIs, SNRIs, gabapentin, and especially neurokinin receptor antagonists have expanded therapeutic options for women who are unsuitable for hormonal therapy.

Emerging advances in molecular medicine, pharmacogenomics, microbiome research, endothelial biomarkers, cardiovascular imaging, and artificial intelligence are expected to transform future menopause care toward precision medicine–based individualized therapy. Future research should focus on long-term cardiovascular outcomes of newer hormonal and non-hormonal agents, optimization of risk-stratified therapeutic algorithms, and development of targeted interventions addressing vascular aging and endothelial dysfunction. A deeper understanding of menopause-associated cardiovascular biology will be essential for improving long-term cardiovascular, metabolic, and quality-of-life outcomes in postmenopausal women.

### REFERENCES

1. Nelson HD. Menopause. *Lancet*. 2008; 371(9614): 760-70.
2. Sherman S. Defining the menopausal transition. *Am. J. Med.*, 2005; 118(12 Suppl 2): 3-7.
3. Hall JE. Endocrinology of the menopause. *Endocrinol. Metab. Clin. North Am.*, 2015; 44(3): 485-96.
4. World Health Organization. Research on the menopause in the 1990s. Geneva: WHO; 1996.
5. The North American Menopause Society. The 2022 hormone therapy position statement of The North

- American Menopause Society. *Menopause*. 2022; 29(7): 767-94.
6. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016; 19(2): 109-50.
  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002; 288(3): 321-33.
  8. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. *J. Clin. Endocrinol. Metab.*, 2010; 95(7 Suppl 1): s1-s66.
  9. Wenger NK, Arnold A, Merz CNB, et al. Hypertension across a woman's life cycle. *J Am Coll Cardiol*. 2018; 71(16): 1797-1813.
  10. Reckelhoff JF. Gender differences in the regulation of blood pressure. *Hypertension*. 2001; 37(5): 1199-1208.
  11. Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. *Curr. Hypertens. Rep.*, 2012; 14(3): 254-260.
  12. Yanes LL, Romero DG, Iliescu R, et al. Postmenopausal hypertension: role of the renin angiotensin system. *Hypertension*. 2010; 56(3): 359-363.
  13. Thurston RC, Joffe H. Vasomotor symptoms and menopause. *Lancet*. 2011; 378(9804): 1851-61.
  14. Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flashes. *JAMA Intern. Med.*, 2015; 175(4): 531-539.
  15. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern. Med.*, 2015; 175(4): 531-539.
  16. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. *Endocrinol. Metab. Clin. North Am.*, 2015; 44(3): 497-515.
  17. Kaunitz AM, Manson JE. Management of menopausal symptoms. *Obstet. Gynecol.*, 2015; 126(4): 859-876.
  18. Lobo RA. Hormone-replacement therapy: current thinking. *Nat. Rev. Endocrinol.*, 2017; 13(4): 220-31.
  19. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. *Climacteric.*, 2005; 8(1): 3-12.
  20. Chakrabarti S, Davidge ST. Estrogen and endothelial function. *Cell Mol. Life Sci.*, 2009; 66(7): 1203-1217.
  21. Moreau KL, Hildreth KL, Meditz AL, et al. Endothelial function in postmenopausal women. *Menopause*. 2012; 19(7): 830-835.
  22. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. *Clin. Sci.*, 2011; 120(9): 357-375.
  23. Yanes LL, Romero DG, Iliescu R, Zhang H, Reckelhoff JF. Postmenopausal hypertension: role of the renin angiotensin system. *Hypertension*. 2010; 56(3): 359-363.
  24. Hypertension in postmenopausal women Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. *Curr. Hypertens. Rep.*, 2012; 14(3): 254-260.
  25. Gender differences in the regulation of blood pressure Reckelhoff JF. Gender differences in the regulation of blood pressure. *Hypertension*. 2001; 37(5): 1199-1208.
  26. The protective effects of estrogen on the cardiovascular system Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N. Engl. J. Med.*, 1999; 340(23): 1801-1811.
  27. Donato AJ, Eskurza I, Silver AE, et al. Direct evidence of endothelial oxidative stress. *Circ. Res.*, 2007; 100(11): 1659-1666.
  28. Harrison DG, Gongora MC. Oxidative stress and hypertension. *Med. Clin. North Am.*, 2009; 93(3): 621-635.
  29. Hogarth AJ, Mackintosh AF, Mary DASG. Sympathetic nerve hyperactivity and its effect in postmenopausal women. *J Hypertens*. 2011; 29(11): 2167-2175.
  30. Aeri BT, Arora S. Autonomic functions in postmenopausal women. *Indian J. Physiol. Pharmacol.*, 2004; 48(4): 525-530.
  31. Carr MC. The emergence of the metabolic syndrome with menopause. *J. Clin. Endocrinol. Metab.*, 2003; 88(6): 2404-2411.
  32. Insulin resistance in postmenopausal women with metabolic syndrome Chu MC, Cospers P, Nakhuda GS, Lobo RA. Insulin resistance in postmenopausal women with metabolic syndrome. *Am. J. Obstet. Gynecol.*, 2006; 195(6): e1-e7.
  33. Metabolic Disorders in Menopause Jeong HG, Park H. Metabolic disorders in menopause. *Int. J. Mol. Sci.*, 2022; 23(18): 10782.
  34. Schiffrin EL. Vascular remodeling in hypertension. *Hypertension*. 2012; 59(2): 367-374.
  35. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. *Hypertension*. 2000; 36(3): 312-318.
  36. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness. *Circulation*. 2003; 107(22): 2864-2869.
  37. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness. *Eur. Heart J*. 2006; 27(21): 2588-2605.
  38. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events with arterial stiffness. *J. Am. Coll. Cardiol.*, 2010; 55(13): 1318-1327.
  39. Xing D, Nozell S, Chen YF, et al. Estrogen and vascular inflammation. *Arterioscler. Thromb. Vasc. Biol.*, 2009; 29(3): 289-295.

40. Reactive oxygen species in vascular biology Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. *Hypertension*. 2004; 44(3): 248-252.
41. Oxidative stress and hypertension Harrison DG, Gongora MC. Oxidative stress and hypertension. *Med. Clin. North Am.*, 2009; 93(3): 621-635.
42. Vascular remodeling in hypertension Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. *Hypertension*. 2012; 59(2): 367-374.
43. Clinical application of C-reactive protein for cardiovascular disease detection and prevention Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 2003; 107(3): 363-369.
44. Endothelial function in postmenopausal women Moreau KL, Hildreth KL, Meditz AL, et al. Endothelial function in postmenopausal women and effects of estrogen. *Menopause*. 2012; 19(7): 830-835.
45. Carr MC. The emergence of the metabolic syndrome with menopause. *J. Clin. Endocrinol. Metab.*, 2003; 88(6): 2404-2411.
46. Metabolic disorders in menopause Jeong HG, Park H. Metabolic disorders in menopause. *Int. J. Mol. Sci.*, 2022; 23(18): 10782.
47. Insulin resistance in postmenopausal women with metabolic syndrome Chu MC, Cosper P, Nakhuda GS, Lobo RA. Insulin resistance in postmenopausal women with metabolic syndrome. *Am. J. Obstet. Gynecol.*, 2006; 195(6): e1-e7.
48. Contribution of abdominal adiposity to age-related differences in insulin sensitivity DeNino WF, Tchernof A, Dionne IJ, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. *Diabetes Care*. 2001; 24(5): 925-932.
49. Regulation of adipocytokines and insulin resistance Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. *Diabetologia*. 2003; 46(12): 1594-1603.
50. Postmenopausal hypertension: role of the renin angiotensin system Yanes LL, Romero DG, Iliescu R, et al. Postmenopausal hypertension: role of the renin angiotensin system. *Hypertension*. 2010; 56(3): 359-363.
51. Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons. *Front Neuroendocrinol*. 2013; 34(3): 211-227.
52. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flashes Prague JK, Roberts RE, Comminos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flashes. *Lancet*. 2017; 389(10081): 1809-1820.
53. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1). *Lancet*. 2023; 401(10382): 1091-1102.
54. Duration of menopausal hot flushes Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes. *JAMA Intern. Med.*, 2015; 175(4): 531-539.
55. Thurston RC, Joffe H. Vasomotor symptoms and menopause. *Lancet*. 2011; 378(9804): 1851-1861.
56. Duration of menopausal vasomotor symptoms over the menopause transition Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern. Med.*, 2015; 175(4): 531-539.
57. Wenger NK, Arnold A, Merz CNB, et al. Hypertension across a woman's life cycle. *J Am Coll. Cardiol.*, 2018; 71(16): 1797-1813.
58. Current perspectives on arterial stiffness Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. *Circulation*. 2003; 107(22): 2864-2869.
59. Prediction of cardiovascular events with arterial stiffness Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events with arterial stiffness. *J Am. Coll. Cardiol.*, 2010; 55(13): 1318-1327.
60. Ageing as a risk factor for neurodegenerative disease Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol*. 2019; 15(10): 565-581.
61. Mitochondrial dysfunction in atherosclerosis Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. *Circ. Res.*, 2007; 100(4): 460-473.
62. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2022; 29(7): 767-794.
63. 2016 IMS recommendations on women's midlife health and menopause hormone therapy Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016; 19(2): 109-150.
64. Management of menopausal symptoms Kaunitz AM, Manson JE. Management of menopausal symptoms. *Obstet Gynecol*. 2015; 126(4): 859-876.
65. Treatment of symptoms of menopause Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of menopause. *J. Clin. Endocrinol. Metab.*, 2015; 100(11): 3975-4011.
66. Lobo RA, Gershenson DM, Lentz GM, Valea FA, editors. *Menopause practice: a clinician's guide*. 6th ed. Cleveland: North American Menopause Society; 2019.
67. Stevenson JC. Type of oestrogen and route of administration. *Climacteric*. 2009; 12(1): 86-90.
68. Lambrinoudaki I, Ceausu I, Depypere H, et al. EMAS clinical guide: low-dose hormone therapy for

- postmenopausal women. *Maturitas*. 2014; 79(1): 83-88.
69. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N Engl J Med*. 1999; 340(23): 1801-1811.
70. Vascular actions of estrogens: functional implications Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. *Pharmacol. Rev.*, 2008; 60(2): 210-241.
71. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery Shufelt CL, Manson JE. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery. *J. Clin. Endocrinol. Metab.*, 2021; 106(5): 1245-1254.
72. Hormone therapy and venous thromboembolism among postmenopausal women Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women. *Circulation*. 2007; 115(7): 840-845.
73. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy. *Menopause*. 2013; 20(12): 1292-1299.
74. Micronized progesterone: vaginal and oral uses Simon JA. Micronized progesterone: vaginal and oral uses. *Clin. Obstet. Gynecol.*, 2018; 61(3): 463-476.
75. Progesterone for symptomatic menopausal women Prior JC. Progesterone for symptomatic menopausal women. *Climacteric.*, 2018; 21(4): 358-365.
76. Unequal risks for breast cancer associated with different hormone replacement therapies Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies. *Breast Cancer Res. Treat.*, 2008; 107(1): 103-111.
77. Dubey RK, Jackson EK. Estrogen-induced cardioprotection. *Cardiovasc. Res.*, 2001; 53(3): 688-708.
78. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. *Pharmacol. Ther.*, 2012; 135(1): 54-70.
79. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. *Clin. Pharmacol. Ther.*, 2011; 89(1): 44-55.
80. Guttuso T Jr, Kurlan R, McDermott MP, Kiebertz K. Gabapentin's effects on hot flashes in postmenopausal women. *Neurology*. 2003; 61(9): 1215-1218.
81. Low-dose paroxetine for menopausal vasomotor symptoms Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine for menopausal vasomotor symptoms. *Menopause*. 2013; 20(10): 1027-1035.
82. Gabapentin's effects on hot flashes in postmenopausal women Guttuso T Jr, Kurlan R, McDermott MP, Kiebertz K. Gabapentin's effects on hot flashes in postmenopausal women. *Neurology*. 2003; 61(9): 1215-1218.
83. Extended-release oxybutynin therapy for vasomotor symptoms Simon JA, Gaines T, LaGuardia KD. Extended-release oxybutynin therapy for vasomotor symptoms. *Menopause*. 2016; 23(11): 1214-1221.
84. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1). *Lancet*. 2023; 401(10382): 1091-1102.
85. Santoro N, Waldbaum A, Lederman S, et al. Effect of fezolinetant on sleep outcomes in menopausal women. *Obstet Gynecol.*, 2023; 141(4): 737-747.
86. Pinkerton JV, Kingsberg SA, Kagan R, et al. Elinzanetant for vasomotor symptoms associated with menopause. *JAMA Intern. Med.*, 2025; 185(2): 145-156.
87. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. *Front Neuroendocrinol.*, 2010; 31(4): 400-419.
88. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a systematic review and meta-analysis. *Obstet. Gynecol.*, 2015; 126(4): 859-876.
89. Messina M. Soy and health update: evaluation of the clinical and epidemiologic literature. *Nutrients*. 2016; 8(12): 754.
90. Adlercreutz H. Phytoestrogens and breast cancer. *J. Steroid Biochem. Mol. Biol.*, 2002; 83(1-5): 113-118.
91. Rietjens IM, Louisse J, Beekmann K. The potential health effects of dietary phytoestrogens. *Br. J. Pharmacol.*, 2017; 174(11): 1263-1280.
92. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. *J. Nutr.*, 1999; 129(3): 758S-767S.
93. Squadrito F, Altavilla D, Crisafulli A, et al. Effect of genistein on endothelial function in postmenopausal women. *Am. J. Med.*, 2003; 114(6): 470-476.
94. Genistein and cardiovascular disease Si H, Liu D. Genistein and cardiovascular disease. *Nutrients*. 2014; 6(12): 5515-5532.
95. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. *Ann. Intern. Med.*, 2007; 146(12): 839-847.
96. The clinical importance of the metabolite equol Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol. *J. Nutr.*, 2002; 132(12): 3577-3584.
97. Is equol the key to the efficacy of soy foods? Lampe JW. Is equol the key to the efficacy of soy foods? *Am. J. Clin. Nutr.*, 2009; 89(5): 1664S-1667S.
98. Lampe JW. Is equol the key to the efficacy of soy foods? *Am. J. Clin. Nutr.*, 2009; 89(5): 1664S-1667S.
99. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. *Cochrane Database Syst. Rev.*, 2013; (12): CD001395.
100. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of soy protein intake and serum lipids. *N. Engl. J. Med.*, 1995; 333(5): 276-282.

101. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. *Ann.Intern. Med.*, 2007; 146(12): 839-847.
102. Hodis HN, Mack WJ. A "window of opportunity": timing hypothesis for cardiovascular effects of estrogen therapy. *Menopause.* 2011; 18(3): 342-347.
103. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy. *Menopause.* 2013; 20(3): 342-353.
104. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N. Engl. J. Med.*, 1999; 340(23): 1801-11.
105. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. *Pharmacol. Rev.* 2008; 60(2): 210-241.
106. Collins FS, Varmus H. A new initiative on precision medicine. *N. Engl. J. Med.*, 2015; 372(9): 793-795.
107. Lobo RA. Precision medicine and menopause management. *Climacteric.* 2019; 22(1): 15-21
108. Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons. *Front Neuroendocrinol.*, 2013; 34(3): 211-227.
109. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes. *JAMA.* 2011; 305(3): 267-274.
110. Murphy E. Estrogen signaling and cardiovascular disease. *Circ. Res.*, 2011; 109(6): 687-696.
111. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Hypertension.* 2018; 71(6): e13-e115.
112. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. *N. Engl. J. Med.*, 1997; 336(16): 1117-24.
113. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur. Heart J.*, 2018; 39(33): 3021-104.
114. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? *J. Am Coll Cardiol.*, 2018; 71(13): 1474-82.
115. Burnier M, Egan BM. Adherence in hypertension. *Circ. Res.*, 2019; 124(7): 1124-40.
116. Volpe M, Azizi M, Danser AHJ, Nguyen G, Ruilope LM. Twisting arms to angiotensin receptor blockers/angiotensin converting enzyme inhibitors: the turn of RAAS blockade toward protective strategies. *Eur Heart J.* 2019; 40(14): 1132-5.
117. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N. Engl. J. Med.*, 2008; 358(15): 1547-59.
118. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med.* 1999;341(10):709-17.
119. Messerli FH, Grossman E, Goldbourt U. Are  $\beta$ -blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA.* 1998; 279(23): 1903-7.
120. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. *Hypertension.* 2012; 59(6): 1110-7.
121. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. *J Am Coll Cardiol.*, 2008; 52(18): 1482-9.
122. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. *Circulation.* 2001; 104(5): 511-4.
123. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. *Hypertension.* 1999; 33(5): 1190-4.
124. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. *Am J Hypertens.* 2005; 18(6): 797-804.
125. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. *Hypertension.* 2018; 72(5): e53-e90.
126. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Böck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J.* 2021; 42(34): 3227-337.
127. Dzau VJ, Balatbat CA. Future of hypertension. *Hypertension.* 2019; 74(3): 450-7.